Is the price fair?
What CRON's price assumes
Cronos Group Inc. trades at 355× earnings against 24.4× for the median Drug Manufacturers - Specialty & Generic name, more expensive than its own group.
355
Trailing P/E · Drug Manufacturers - Specialty & Generic median 24.4 · 14.6× the median: the market pays up for this one
- Price / sales
- 6.01
Price / sales · as of 2026-Q1
- Free cash flow yield
- 2.6%
Free cash flow yield · Drug Manufacturers - Specialty & Generic median 4.5%
- Growth the price implies
- +14%
Growth the price implies · The price pays for +14% free cash flow growth a year for a decade; revenue has grown +24% a year over the last three.
Details›
- Price / book2026-Q1
- 0.89
- EV / EBIToperating margin −9.5%: the multiple describes the denominator
- not meaningful
- Healthcare median P/E362 names
- 31.5
- Drug Manufacturers - Specialty & Generic median P/E32 names
- 24.4
- Free cash flow, trailing twelve months
- $27M
- Market capitalisation
- $1.01B
- 3-year revenue growth
- +24%
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.
Drug Manufacturers - Specialty & Generic
Ranks #4 of 28 by Smart Score